Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104066 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CA2TDP1CYP3A4TSHR | |
| SCHEMBL23498284 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CA2TDP1CYP3A4TSHR | |
| SCHEMBL3101340 | 0.95 | LMNA (0.50) | ALDH1A1CA2TDP1CYP3A4TSHR | |
| SCHEMBL11607418 | 0.95 | LMNA (0.50) | ALDH1A1CA2TDP1CYP3A4TSHR | |
| SCHEMBL3084643 | 0.95 | LMNA (0.50) | ALDH1A1CA2TDP1CYP3A4TSHR | |
| SCHEMBL3093790 | 0.91 | LMNA (0.50) | ALDH1A1CA2TDP1CYP3A4TSHR | |
| SCHEMBL3100767 | 0.91 | CA2 (0.41) | ALDH1A1CA2TDP1CYP3A4TSHR | |
| SCHEMBL976399 | 0.90 | ALDH1A1 (0.54) | ALDH1A1CA2TDP1CYP3A4TSHR | |
| SCHEMBL3090932 | 0.88 | CA2 (0.42) | ALDH1A1CA2TDP1CYP3A4TSHR | |
| SCHEMBL3097258 | 0.88 | CA2 (0.47) | ALDH1A1CA2TDP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, LLC (US) | 2010-11-04 | — | — | US | disclosed |
| US-7799954-B2 | Dicarbonyl derivatives and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7674816-B2 | Substituted melatonin derivatives, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2125694-A2 | DICARBONYL DERIVATIVES AND METHODS OF USE | Abraxis BioScience, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1701718-A4 | SUBSTITUTED MELATONIN DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE | ABRAXIS BIOSCIENCE LLC (US) | 2009-06-24 | — | — | EP | disclosed |
| EP-1976505-A1 | COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS | Abraxis BioScience, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008064060-A2 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070191463-A1 | Substituted melatonin derivatives, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, INC. (CA) | 2007-08-16 | — | — | US | disclosed |
| WO-2007059118-A1 | COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-5597846-A | ESTERS OF RADICICOL | SANKYO COMPANY, LIMITED (JP) | 1997-01-28 | — | — | US | disclosed |
| US-5559109-A | Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist | SANKKO COMPANY, LIMITED (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5556852-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0395446-B1 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | SANKYO CO (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5369106-A | N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists | SANKYO COMPANY, LIMITED (JP) | 1994-11-29 | — | — | US | disclosed |
| US-5192766-A | Platelet activating factor antagonist | SANKYO COMPANY, LIMITED (JP) | 1993-03-09 | — | — | US | disclosed |
| CN-1059720-A | Radicicol derivatives, its preparation method and anti-tumor activity thereof | SANKYO CO (JP) | 1992-03-25 | — | — | CN | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
| EP-0395446-A2 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | Sankyo Company Limited (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | ALDH1A1 1688/4885CA2 1127/4885TDP1 2676/4885 |
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | ALDH1A1 1688/4885CA2 1127/4885TDP1 2676/4885 |
| US-20070191463-A1 | Substituted melatonin derivatives, process for their preparation, and methods of use | MTNR1B, MTNR1A, CYP3A5 | ALDH1A1 892/4885CA2 2602/4885TDP1 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.